Cargando…

In Silico Food-Drug Interaction: A Case Study of Eluxadoline and Fatty Meal

Food-drug interaction is an infrequently considered aspect in clinical practice. Usually, drugs are taken together with meals and what follows may adversely affect pharmacokinetic and pharmacodynamic properties, and hence, the therapeutic effects. In this study, a computational protocol was proposed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maruca, Annalisa, Lupia, Antonio, Rocca, Roberta, Keszthelyi, Daniel, Corsetti, Maura, Alcaro, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731208/ https://www.ncbi.nlm.nih.gov/pubmed/33266221 http://dx.doi.org/10.3390/ijms21239127

Ejemplares similares

Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
por: Coricello, Adriana, et al.
Publicado: (2020)

Chemoinformatic Database Building and in Silico Hit-Identification of Potential Multi-Targeting Bioactive Compounds Extracted from Mushroom Species
por: Maruca, Annalisa, et al.
Publicado: (2017)

In Silico Identification and Biological Evaluation of Antioxidant Food Components Endowed with Human Carbonic Anhydrase IX and XII Inhibition
por: Costa, Giosuè, et al.
Publicado: (2020)

Multi-Targeting Bioactive Compounds Extracted from Essential Oils as Kinase Inhibitors
por: Maruca, Annalisa, et al.
Publicado: (2020)

Uncovering Novel Capsaicin Inhibitory Activity towards Human Carbonic Anhydrase Isoforms IX and XII by Combining In Silico and In Vitro Studies
por: Gualtieri, Gianmarco, et al.
Publicado: (2023)

Natural Products Extracted from Fungal Species as New Potential Anti-Cancer Drugs: A Structure-Based Drug Repurposing Approach Targeting HDAC7
por: Maruca, Annalisa, et al.
Publicado: (2020)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Evaluation of Eluxadoline Effect on Cardiac Repolarization
por: Bonifacio, Laura, et al.
Publicado: (2018)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Özdener, Ayşe Elif, et al.
Publicado: (2017)

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
por: Cash, Brooks D, et al.
Publicado: (2017)

Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
por: Fragkos, Konstantinos C
Publicado: (2017)

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016)

Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets
por: Romeo, Isabella, et al.
Publicado: (2021)

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use
por: Lacy, Brian E, et al.
Publicado: (2017)

Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives
por: Liu, Rebecca, et al.
Publicado: (2020)

HSV-1 Glycoprotein D and Its Surface Receptors: Evaluation of Protein–Protein Interaction and Targeting by Triazole-Based Compounds through In Silico Approaches
por: Bivacqua, Roberta, et al.
Publicado: (2023)

Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers
por: Fujita, Wakako, et al.
Publicado: (2014)

Eluxadoline Loaded Solid Lipid Nanoparticles for Improved Colon Targeting in Rat Model of Ulcerative Colitis
por: Anwer, Md. Khalid, et al.
Publicado: (2020)

Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change
por: Cash, Brooks D., et al.
Publicado: (2021)

An Open‐Label Study to Evaluate the Effect of Eluxadoline on the Single‐Dose Pharmacokinetics of Midazolam in Healthy Participants
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Single‐dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis
por: Qin, Di, et al.
Publicado: (2022)

Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties
por: Rocca, Roberta, et al.
Publicado: (2022)

The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea
por: Abel, Jessica L., et al.
Publicado: (2018)

Tolerability, gastric emptying patterns, and symptoms during the Nottingham Test Meal in 330 secondary care non‐diabetic dyspeptic patients
por: Hay, Peter D., et al.
Publicado: (2022)

Probing Substituents in the 1- and 3-Position: Tetrahydropyrazino-Annelated Water-Soluble Xanthine Derivatives as Multi-Target Drugs With Potent Adenosine Receptor Antagonistic Activity
por: Koch, Pierre, et al.
Publicado: (2018)

Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline
por: Davenport, J Michael, et al.
Publicado: (2015)

Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome
por: Anwer, Md. K., et al.
Publicado: (2017)

Eluxadoline-induced Recurrent Pancreatitis in a Young Female without a Gallbladder: A Case Report and Literature Review
por: Khetpal, Neelam, et al.
Publicado: (2018)

Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials
por: Lacy, Brian E., et al.
Publicado: (2019)

Effects of treatment with eluxadoline on abdominal pain in patients with IBS‐D: Additional post hoc analyses of Phase 3 trials
por: Lembo, Anthony J., et al.
Publicado: (2020)

The Mu.Ta.Lig. Chemotheca: A Community-Populated Molecular Database for Multi-Target Ligands Identification and Compound-Repurposing
por: Ortuso, Francesco, et al.
Publicado: (2018)

The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma
por: Grillone, Katia, et al.
Publicado: (2022)

In Silico and In Vitro Study of Antioxidant Potential of Urolithins
por: Marchese, Emanuela, et al.
Publicado: (2023)

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies
por: Chey, W. D., et al.
Publicado: (2017)

Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box–Behnken Design, and Anti-Diarrheal Activity
por: Anwer, Md. Khalid, et al.
Publicado: (2023)

Officers' Food and the Regulation of Meals
Publicado: (1886)

Officers' Food, and the Regulation of Meals
Publicado: (1886)

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist
por: Levy-Cooperman, N., et al.
Publicado: (2016)

Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study
por: Brenner, Darren M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sqd2sgtttc3rue7g41fn6r2d9e